国内明星创新药企和黄医药去年收入、净收益双降,但核心产品海外销售额表现亮眼。 3月19日晚间,和黄医药(中国)有限公司(和黄医药,0013.HK)公布2024年业绩。报告期内,总收入6.3亿美元,较2023年同期的8.38亿美元相比下降约24%;应占净收益3772.9万美元,同比下降约62%。 和黄医药2024年收入等数据 和黄医药成立于2000年,2021年在港股上市,业务聚焦在肿瘤、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.